NCT07076108Completed
Oral Vitamin C Administration on Erythropoietin Dosing Requirement in End-Stage Renal Disease Patients on Regular Hemodialysis
The Safety and Efficacy of Oral Vitamin C Administration on Erythropoietin Dosing Requirement in End-Stage Renal Disease Patients on Regular Hemodialysis
Source: ClinicalTrials.gov · Last updated 18 Dec 2025
Brief summary (registry, in English)
The study aimed to evaluate the safety and efficacy of oral vitamin C administration on erythropoietin dosing requirement in end-stage renal disease patients on regular hemodialysis.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 60 (actual)
- First submitted
- 13 Jul 2025
- Start date
- 1 Aug 2019
- Primary completion date
- 28 Apr 2024
- Lead sponsor
- Ain Shams University
- Diseases
- Chronic kidney disease
- NCT number
- NCT07076108
What you commit to
- Study type: Interventional
- Participants enrolled: 60
- From 1 Aug 2019 to the primary completion date, 28 Apr 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Patients with gastrointestinal bleeding.
- Blood transfusion, malignancy.
- Hospital admission or history of noncompliance with dialysis and/or medication were excluded from the study and were also censored if these events occurred during the study period.
Who the study is looking for
- Age \>18 years.
- Both sexes.
- Stable hemodialysis (HD) for 90 days or more
- Hemoglobin (HB) levels of 9-11 g/dL (as Hb levels above 11 g/dL, Epo dose reduction is recommended irrespective of iron level).
- Erythropoietin (EPO) dose ≥4000 U/HD session and unchanged dose for two consecutive months
- Ferritin level \>100 mcg/L.
- Transferrin saturation (Tsat) of \<30 %.
- Not on a vitamin C supplement.
- Not receiving iron supplementation in the preceding 2 months. Each patient's previous 2-month stable dose of Epo was taken as the control.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Ain Shams University Coordinator of this site? Confirm its status | Cairo | Egypt | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.